Cell Therapeutics, Ready To Tap Financing (CTIC)
Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants. Last Tuesday, the company announced progress in beginning Phase…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants.
Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.
Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66. The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.
Rachel Lopez
March 31, 2008
Contact [email protected] for any questions or corrections.